Establishment and characterization of monoclonal 5-fluorouracil-resistant cell lines derived from human endometrial adenocarcinoma

International Journal of Oncology

Volumn 37, Issue 3, 2010, Pages 731-736

  Tanaka, Tetsuji ^a   Bai, Tao ^a   Toujima, Saori ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Drug resistance; Endometrial adenocarcinoma; Fas; Fluorouracil; Karyotype

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BLEOMYCIN; ETOPOSIDE; FLUOROURACIL; MITOMYCIN; PACLITAXEL; PIRARUBICIN;

ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CARCINOMA CELL; CELL CLONE; CELL CULTURE; CELL DEATH; CHROMOSOME DELETION; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG SENSITIVITY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; KARYOTYPING; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; KARYOTYPING;

EID: 77956546746     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000722     Document Type: Article

References (9)

1. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, De Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
2. Pectasides D, Pectasides M, Farmakis D, Gaglia A, Koumarianou A, Nikolaou M, Koumpou M, Kountourakis P, Papaxoinis G, Mitrou P, Economopoulos T and Raptis SA: Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol 95: 165-172, 2004.
3. Rosa DD, Awada A, Mano MS, Selleslags J, Lebrun F, Gil T, Piccart MJ and D'Hondt V: Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma. Arch Gynecol Obstet 278: 457-462, 2008.
4. Ishiwata I, Ishiwata C, Soma M, Arai J and Ishikawa H: Establishment of human endometrial adenocarcinoma cell line containing estradiol-17 beta and progesteron receptors. Gynecol Oncol 17: 281-290, 1984. (Pubitemid 14174339)
5. Tanaka T, Nakajima S and Umesaki N: Cellular heterogeneity in long-term surviving cells isolated from eutopic endometrial, ovarian endometrioma and adenomyosis tissues. Oncol Rep 10: 1150-1160, 2003.
6. Gibas Z, Prout GR, Conolly JG, Pontes JE and Sandberg AA: Non-random chromosome changes in transitional cell carcinoma of the bladder. Cancer Res 44: 1257-1264, 1984. (Pubitemid 14151537)
7. Yoshida MA, Ohyashiki K, Ochi H, Gibas Z, Pontes JE, Prout GR Jr, Huben R and Sandberg AA: Cytogenetic studies of tumor tissue from patients with non-familial renal cell carcinoma. Cancer Res 46: 2139-2147, 1986.
8. Yunis JJ: New chromosome techniques in the study of human neoplasia. Hum Pathol 12: 540-549, 1981.
9. Tanaka T and Umesaki N: Cytokine regulation of apoptotic susceptibility in a human endometrial epithelial cell line. J Reprod Immunol 47: 105-119, 2000. (Pubitemid 30621430)